Each chapter of Selling Sickness takes as its topic a strategy for influencing, and constituting, the health consumer, with reference, in each case, to a particular disorder or condition. So, for example, the industry strategy of expanding the pool of potential consumers by widening the definition of a disorder is described with reference to high cholesterol. (With the rewriting of guidelines for high cholesterol in 2001, the number of candidates for drug treatment increased in the United States from thirteen million to 36 million; five of the fourteen authors of the new guidelines had financial ties to manufacturers of cholesterol-lowering drugs [pp. 3-4] .
3 ) The strategy of sponsoring -grass roots‖ partnerships in order to exploit them for pharmaceutical sales is described with reference to attention deficit disorder. (CHADD [Children and Adults with AttentionDeficit/Hyperactivity Disorders] receives approximately $700,000 a year from pharmaceutical companies; the organization is committed to a description of ADHD as a -common ‗neurobiological' disorder to be treated primarily with drugs‖ [p. 65] .) The strategy of creating an identity for a disease and advertising the disease directly to consumers, along with a drug for treating it, is described with reference to premenstrual dysphoric disorder. (While some-mostly pharmaceutical industry sponsored-experts say that PMDD -is a psychiatric condition suffered by up to 7 percent of women,‖ and treatable by antidepressants, other experts do not recognize PMDD as a disease at all; but controversy about the existence of PMDD is invisible -in the avalanche of television and magazine advertisements about PMDD,‖ most of them targeting young and healthy, women [99] [100] .)
In the case of each strategy and each condition or disorder, Moynihan and Cassels are not simply anti-drug; certainly, they say, sick people benefit from having access to the right drug at the right time. Rather they urge a complex view of conditions that tend to be oversimplified by drug advertisers for commercial ends. One example: cholesterol-lowering drugs are a $25 billion a year industry. While, for some people, a raised level of blood cholesterol is associated with risk of heart attack and stroke, it is known that -for otherwise healthy people at low risk, long-term use of [cholesterollowering drugs] may offer little benefit and unknown harms‖ (p. 11). Accordingly, Moynihan and Cassels explain that World Health Organization officials object to the implication that -smokers, obese individuals, or those who live a sedentary lifestyle can safely continue to smoke, remain overweight, or take little exercise, provided they take medication to reduce their cholesterol values‖ (WHO, quoted on p. 15). Cholesterollowering drugs have their uses, but the marketplace saturation of the drug is not medically warranted and may be harmful.
Selling Sickness is not unduly alarmist, but it does deliver a strong message on the public health dangers of over-focusing on pharmaceuticals. Not only can a surfeit of attention to drugs reduce the understanding of heart disease to a collection of cholesterol and blood pressure numbers, it can also turn hip fracture prevention into an obsession with measurements of bone density, 4 and it can reconfigure emotional distress as -chemical imbalance,‖ treatable with drugs. With such shifts, physicians become less able to understand whole persons in their social contexts. While Moynihan and Cassels point out that pharmaceutical manufacturers are -[r]ightly rewarded for saving life and reducing suffering‖ (p. x), they argue that pharmaceuticals are complex and problematic entities-and that (as we, in our field, know very well) highlighting one thing means hiding another.
If there were a weakness in this book, it would be that its position against the marketing maneuvers of big pharmaceutical companies is so unabashed that one might wonder if the authors are sufficiently even-handed in their reporting. Notwithstanding its deployment of the usual disclaimers (as I've said, the authors make a point of giving credit to pharmaceutical companies where it's due), the book is an argument against aggressive advertising and consequent over-prescription. The book even offers us a cast of ethical physician-heroes, who embody the promise of resistance to pharmaceutical marketers. Dr. Iona Heath fights for the care of the -sick poor‖ against the -healthy rich‖ (why, she asks, are so many health care resources diverted to people who are basically well? [p. 16]); Dr. Warren Bell refuses even to accept the visits of pharmaceutical sales representatives in his practice (p. 38); Australian physician Peter Mansfield is an -indefatigable‖ critic of misleading direct-to-consumer pharmaceutical advertising (p. 102). I am not sure, however, that Moynihan and Cassels' bias is a weakness. I have discovered, over the course of my own research, that there is almost nothing you can say about drug marketers that they haven't already said about themselves-with pride: we know about -condition branding,‖ for example, because marketing specialist Vince Parry describes it, earnestly, as a great way to sell drugs.
5
Because of Selling Sickness, with its trenchant criticism and its clearly marked good guys and bad guys, pharmaceutical apologists will have to answer charges that drug marketers are opportunistic, greedy, and single-minded; that's fine with me.
In fact, we are not, most of us, in a position directly to teach the subject matter of Selling Sickness. Few of us are expert in diagnosis and treatment for conditions from irritable bowel syndrome to -female sexual dysfunction.‖ Selling Sickness is useful to us and our students because it offers ways of thinking about persuasion and the choices of rhetors on matters of health and medicine in a variety of genres-not only pharmaceutical advertisements, but also scientific articles, conference presentations, doctor-patient interviews, treatment guidelines, and illness support group web pages. The focus of Selling Sickness on strategy is, by another name, a focus on rhetoric. The originators of the many texts that make up the core of interest in Selling Sickness are professional writers and technical communicators who steer what we think, and how we think, about what's wrong with us and what to do about it. This book ought to be required reading for our students-and everyone else too.
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